1. Introduction {#s0005}
===============

In December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) and the disease it caused, now known as coronavirus disease 2019 (COVID-19), were initially reported in Wuhan, China and rapidly spread throughout the world \[[@bb0005]\]. As of June 25, 2020, more than 9 million laboratory-confirmed cases have been identified in 208 countries and areas, with more than 480,000 fatal cases, according to the data from World Health Organization (WHO) reports \[[@bb0010]\].

.In recent studies documenting the clinical features of confirmed patients with COVID-19, it has been reported that most of them would present a type of mild infection of the COVID-19 disease \[[@bb0015],[@bb0020]\]. However, a number of patients were observed to present with severe infection on admission with high mortality. Therefore, it is crucial to discriminate accurately among subjects with COVID-19 who have a high risk of severe infection and guide the use of different therapies at an early stage. Abnormal coagulation function, including elevated D-dimer, has been demonstrated to be more common in deceased patients with COVID-19, and increasing odds of in-hospital death was associated with D-dimer greater than 1 μg/ml \[[@bb0025],[@bb0030]\]. However, the association between D-dimer and the severity of COVID-19 is not clear.

In our cohort study, epidemiological, clinical characteristics, and coagulation function parameters of patients with confirmed COVID-19 on admission were collected and compared, between patients with severe infection and those with non-severe infection. Further, a meta-analysis including our cohort study was then conducted to evaluate the association between D-dimer levels and severe COVID-19.

2. Materials and methods {#s0010}
========================

2.1. Study design and participants recruited {#s0015}
--------------------------------------------

Totally 1561 patients with COVID-19 were recruited retrospectively from January 27th to March 5th, 2020, at Tongji hospital, the largest comprehensive medical center in Wuhan and the specific hospital for the treatment of patients with severe COVID-19 in Wuhan designated by the Chinese government. Laboratory confirmation of COVID-19 was carried out by real-time reverse-transcriptase--polymerase-chain-reaction (RT-PCR) using method described previously \[[@bb0020]\]. This study was approved by Tongji Hospital Ethics Committee (IRB ID: TJ-C20200121). Written informed consent was waived by the Ethics Commission of Tongji hospital for emerging infectious diseases.

2.2. Data collection from electronic medical records {#s0020}
----------------------------------------------------

Epidemiological characteristics, comorbidities, coagulation function markers on admission and disease severity, were obtained from patients\' medical records. D-dimer were detected using a STA-R MAX coagulation analyzer and original reagents (Diagnostica Stago, Saint-Denis, France). The severity of COVID-19 was defined according to WHO clinical management guidance of COVID-19 \[[@bb0035]\]. Severe type was defined as followed: fever or suspected respiratory infection, plus one of respiratory rate \> 30 breaths/min, severe respiratory distress, or SpO~2~ \< 90% on room air.

2.3. Search strategy of meta-analysis {#s0025}
-------------------------------------

This work has been performed according to PRISMA guidelines (<http://www.prisma-statement.org>). PubMed, Web of Science, Embase, bioRxiv and medRxiv were searched using the following search terms: (2019 novel coronavirus OR 2019-nCoV OR coronavirus disease 2019 OR COVID-19 OR SARS-CoV-2) AND (laboratory OR D-dimer). The search was limited between the December 1, 2019 and March 17, 2020, without language restriction. The studies that reported the value of D-dimer on admission in patients with severe disease and those with non-severe disease, were included in a meta-analysis. Studies from our center (Tongji hospital) were excluded. Two of the authors scanned and selected the studies independently, and any controversies were resolved by discussion, with a kappa of 0.78 for inter-rater agreement.

2.4. Data extraction of meta-analysis {#s0030}
-------------------------------------

The identified name of the study (first author, year of publication), sample size, the value of D-dimer, the number of patients with abnormal D-dimer (≥0.5 μg/ml), were retrieved from the articles directly or by calculation. Two of the authors extracted the corresponding data independently, and any controversies were resolved by discussion. The mean and standard deviation (SD) were imputed when a study only provided median and interquartile ranges, as described in other studies \[[@bb0040],[@bb0045]\].

2.5. Efficacy measures of meta-analysis {#s0035}
---------------------------------------

Differences of mean value of D-dimer between patients with severe disease and patients with non-severe disease, and odds of severe COVID-19 associated with D-dimer greater than 0.5 μg/ml, on admission, were defined as the outcome of the meta-analysis.

2.6. Statistical analysis {#s0040}
-------------------------

For our cohort study, continuous variables were described as medians (IQR), and compared using Mann-Whitney *U* test. Categorical variables were delineated as n (%) and compared by χ^2^ test and Fisher\'s exact test. The association between clinical characteristics and the presence of severe infection were determined by multivariable logistic regression analysis. The results were expressed as odds ratio (OR), 95% confidence intervals (CI), and *p* values. For individual statistical tests on the coagulation function, we calculated a corrected critical P value of 0.0063 (0.05/8 where 8 = the eight tested parameters of coagulation function) using the Bonferroni correction method. For multivariable logistic regression analysis, Bonferroni-Holm (B-H) correction was used to adjust for multiple testing, and results were defined as significant if the *p*-value of the regression analysis was lower or equal as the B-H corrected *p*-value. For all other analyses, the statistical significance was set at 0.05. All tests were two-sided.

For meta-analysis, weighted mean difference (WMD) with 95% confidence interval (95% CI) and odds ratio (OR) with 95% CI, were pooled for differences of D-dimer value and odds of severe COVID-19, respectively. The heterogeneity was evaluated using I^2^ and *p* value based on Chi-square test. I^2^ ≤ 50% or *p* ≥ 0.1 demonstrated no significant heterogeneity, and a fixed-effects model was used. I^2^ \> 50% or *p* \< 0.1 indicated a significant heterogeneity, and a random-effects model was applied. Funnel plot and the Egger\'s test were performed to evaluate publication bias. STATA statistical version 12.0 (Stata Corporation, College Station, Texas, USA) was used for the data analyses.

3. Results {#s0045}
==========

3.1. Clinical characteristics and coagulation function of patients with COVID-19 in our cohort {#s0050}
----------------------------------------------------------------------------------------------

Comparison of characteristics between patients with severe disease and mild cases in our cohort study is shown in [Table 1](#t0005){ref-type="table"} . Among the 1561 patients with confirmed COVID-19, 365 (23.4%) patients were clinically diagnosed with severe infection, and 1196 (76.6%) were diagnosed with mild infection. Older (median 67 years \[interquartile range, IQR 58--73\] vs 60 \[47--68\], *p* \< 0.001) and male (204/365 \[56%\] vs 576/1196 \[48%\], *p* = 0.006) patients were more common in the severe group when compared with those with non-severe disease. More comorbidities, including hypertension (162/365\[44%\] vs 349/1196\[29%\], *p* \< 0.001), diabetes (74/365\[20%\] vs 159/1196\[13%\], *p* = 0.001), chronic obstructive pulmonary disease (11/365\[3%\] vs 11/1196\[1%\], *p* = 0.006), and cardiovascular disease (47/365\[13%\] vs 108/1196\[9%\], *p* = 0.022), were found in patients with severe disease as compared to those with mild COVID-19. It should be interpreted with caution as the *p*-values were not adjusted for multiple testing.Table 1Clinical characteristics and coagulation function of patients with COVID-19.Table 1No. (%)*p* valueAll patients (n = 1561)Mild (n = 1196)Severe (n = 365)Characteristics Age, median (IQR), range, years62 (50--70)60 (47--68)67 (58--73)\<0.001 Sex0.006 Male780 (50)576 (48)204 (56) Female781 (50)620 (52)161 (44) Smoking103 (7)75 (6)28 (8)0.204Comorbidities Chronic obstructive pulmonary disease22 (1)11 (1)11 (3)0.006 Hypertension511 (33)349 (29)162 (44)\<0.001 Cardiovascular disease155 (10)108 (9)47 (13)0.022 Cerebrovascular disease40 (3)29 (2)11 (3)0.323 Chronic liver disease22 (1)18 (2)4 (1)0.388 Diabetes233 (15)159 (13)74 (20)0.001 Tuberculosis20 (1)18 (2)2 (1)0.119 Malignant tumor46 (3)30 (3)16 (4)0.051 Chronic kidney disease35 (2)25 (2)10 (3)0.289Coagulation function, median (IQR) Prothrombin time (s; normal range 11.5--14.5)13.8 (13.2--14.5)13.6 (13.1--14.2)14.4 (13.7--15.4)\<0.001[a](#tf0005){ref-type="table-fn"} Activated partial thromboplastin time (s; normal range 29.0--42.0)38.7 (35.7--42.4)38.5 (35.7--42)39.4 (35.8--43.8)0.009[a](#tf0005){ref-type="table-fn"} Thrombin time (s; normal range 14.0--19.0)16.5 (15.7--17.5)16.4 (15.7--17.3)16.9 (15.8--18.2)\<0.001[a](#tf0005){ref-type="table-fn"} Fibrinogen (g/L; normal range 2.00--4.00)4.6 (3.6--5.7)4.3 (3.4--5.5)5.3 (4.0--6.5)\<0.001[a](#tf0005){ref-type="table-fn"} Fibrin(ogen) degradation products (μg/ml; normal range \< 5.0)4.0 (4.0--6.0)4.0 (4.0--4.5)6.5 (4.0--21.8)\<0.001[a](#tf0005){ref-type="table-fn"} Prothrombin activity (%; normal range 75.0--125.0)91.0 (84.0--99.0)93.0 (86.0--101.0)84.0 (74.0--92.5)\<0.001[a](#tf0005){ref-type="table-fn"} International normalized ratio (normal range 0.80--1.20)1.0 (1.0--1.1)1.0 (1.0--1.1)1.1 (1.1--1.2)\<0.001[a](#tf0005){ref-type="table-fn"} D-dimer (μg/ml; normal range 0.0--0.5)0.7 (0.3--1.6)0.5 (0.3--1.1)1.8 (0.9--4.6)\<0.001[a](#tf0005){ref-type="table-fn"}[^2][^3][^4]

Moreover, patients with severe disease were significantly more likely to exhibit dysregulated coagulation function. Elevated levels of prothrombin time (median 14.4 \[IQR 13.7--15.4\] vs 13.6 \[13.1--14.2\] s, *p* \< 0.001), thrombin time (16.9 \[15.8--18.2\] vs 16.4 \[15.7--17.3\] s, *p* \< 0.001), fibrinogen (5.3 \[4.0--6.5\] vs 4.3 \[3.4--5.5\] g/L, *p* \< 0.001), fibrin(ogen) degradation products (6.5 \[4.0--21.8\] vs 4.0 \[4.0--4.5\] μg/ml, *p* \< 0.001), and international normalized ratio (1.1 \[1.1--1.2\] vs 1.0 \[1.0--1.1\], *p* \< 0.001), and decreased prothrombin activity (84.0 \[74.0--92.5\] vs 93.0 \[86.0--101.0\] %, *p* \< 0.001) were observed in patients with severe disease when compared with non-severe group. Particularly, a significantly increased level of D-dimer (1.8 \[0.9--4.6\] vs 0.5 \[0.3--1.1\] μg/ml, *p* \< 0.001) was found in patients with severe disease ([Table 1](#t0005){ref-type="table"}, [Fig. 1](#f0005){ref-type="fig"} ). Multivariate logistic regression analysis showed presence of severe COVID-19 was associated with prothrombin time longer than 14.5 s (2.71, 2.00--3.67; *p* \< 0.001, B-H corrected significance level: *p* = 0.0029), fibrin(ogen) degradation products greater than 5.0 μg/ml (2.33, 1.74--3.12, *p* \< 0.001, B-H corrected significance level: *p* = 0.0031), and D-dimer greater than 0.5 μg/ml (3.44, 2.29--5.17; *p* \< 0.001, B-H corrected significance level: *p* = 0.0028), on admission, as shown in [Table 2](#t0010){ref-type="table"} . These results suggested that the severity of COVID-19 was associated with coagulation dysfunction in Tongji Hospital.Fig. 1Scatter plots of D-dimer levels in the severe and mild groups in our cohort study. 58 data points are outside the axis limit as 13 patients in mild group and 45 patients in severe group have D-dimer values over the upper limit of measuring range (\>21 μg/ml). Data are shown in median (interquartile range).Fig. 1Table 2Logistics regression of factors associated with severity of COVID-19.Table 2Multivariate analysisBonferroni-Holm corrected *p*-valueOR95% CI*p* valueCharacteristics Age, years1.01(0.99, 1.02)0.070.0045 Sex (male vs female)1.04(0.78, 1.37)0.800.025 Smoking history (yes vs no)1.15(0.68, 1.96)0.610.01Comorbidities (yes vs no) Chronic obstructive pulmonary disease2.17(0.82, 5.74)0.120.005 Hypertension1.48(1.09, 1.99)0.010.0033 Cardiovascular disease0.87(0.57, 1.33)0.510.0083 Cerebrovascular disease0.61(0.27, 1.35)0.220.0063 Chronic liver disease0.75(0.23, 2.44)0.630.013 Diabetes1.24(0.86, 1.78)0.240.0071 Tuberculosis0.23(0.05, 1.09)0.060.0038 Malignant tumor1.73(0.85, 3.49)0.130.0056 Chronic kidney disease0.90(0.39, 2.06)0.800.05Coagulation function Prothrombin time[a](#tf0010){ref-type="table-fn"}, s ≤14.5Reference \>14.52.71(2.00, 3.67)\<0.0010.0029 Activated partial thromboplastin time, s ≤42.0Reference \>42.01.06(0.79, 1.44)0.690.017 Thrombin time, s ≤19.0Reference \>19.01.51(0.97, 2.35)0.070.0042 Fibrinogen, g/L ≤4.00Reference \>4.001.48(1.08, 2.03)0.020.0036 Fibrin(ogen) degradation products, μg/ml \<5.0Reference ≥5.02.33(1.74, 3.12)\<0.0010.0031 D-dimer, μg/ml \<0.5Reference ≥0.53.44(2.29, 5.17)\<0.0010.0028[^5][^6][^7]

3.2. Study selection for meta-analysis in patients with COVID-19 {#s0055}
----------------------------------------------------------------

As shown in [Fig. 2](#f0010){ref-type="fig"} , a total of 699 articles were identified from electronic database after removal of duplicate studies. Finally, 13 studies (including our cohort study) were included for this meta-analysis. The characteristics of these 13 studies were shown in [Table 3](#t0015){ref-type="table"} . Of the 12 studies other than our cohort study, 8 studies reported the absolute value of D-dimer in patients with severe disease and those with non-severe disease \[[@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080], [@bb0085]\]. The odds ratio (OR) of severe infection in patients with D-dimer greater than 0.5 μg/ml were obtained directly or by calculation from our cohort study and 4 other studies \[[@bb0015],[@bb0090], [@bb0095], [@bb0100]\].Fig. 2Flow chart presenting the process of literature search for this meta-analysis.Fig. 2Table 3Characteristics of patients from 12 published studies and our cohort study included in the meta-analysis.Table 3StudyAll patientsNon-severeSevereSample sizeD-dimer (μg/ml)Sample sizeD-dimer (μg/ml)No. of abnormal D-dimerSample sizeD-dimer (μg/ml)No. of abnormal D-dimerCao M et al. \[[@bb0050]\]1950.39(0.28--0.67)1760.37(0.26--0.56)NA190.77(0.43--1.23)NALiu J et al. \[[@bb0055]\]400.6(0.3--0.9)270.4(0.2--0.8)NA130.9(0.7--1.5)NALiu L et al. \[[@bb0060]\]510.28(0.19--0.51)440.28(0.18--0.46)NA70.6(0.28--1.4)NALu HZ et al. \[[@bb0065]\]2650.42(0.29--0.8)2430.39(0.28--0.72)NA220.8(0.5--3.5)NAQian GQ et al. \[[@bb0070]\]910.3(0.11--0.45)820.3(0.11--0.4)NA90.45(0.16--0.49)NAXu Y et al. \[[@bb0075]\]690.5(0.3--1.2)440.5(0.3--0.9)NA252.3(0.6--14.1)NAZhang GQ et al. \[[@bb0080]\]2210.23(0.13--0.49)1660.18(0.12--0.32)NA550.44(0.21--1.30)NAZhang JJ et al. \[[@bb0085]\]810.2(0.1--0.5)430.2(0.1--0.3)NA380.4(0.2--2.4)NAChen X et al. \[[@bb0090]\]254NA209NA19945NA44Guan W et al. \[[@bb0015]\]560NA451NA195109NA65Liu T et al. \[[@bb0095]\]80NA11NA069NA45Qi D et al. \[[@bb0100]\]267NA217NA650NA13Our study15610.7(0.33--1.61)11960.52(0.28--1.13)6213651.77(0.86--4.55)327[^8]

3.3. Higher level of D-dimer in patients with severe COVID-19 {#s0060}
-------------------------------------------------------------

For meta-analysis concerning the mean value of D-dimer, 9 studies (including our cohort study) were included, with 2574 patients in total. The mean value of D-dimer of all patients was 0.34 (standard deviation SD, 0.14) μg/ml, 0.30 (0.12) for patients with non-severe disease, and 0.89 (0.34) for severe patients. Differences of mean value of D-dimer between severe and non-severe group was 0.91 μg/ml (95% confidence interval CI, 0.51--1.31, *p* \< 0.001, I^2^ = 94.7%), after pooling WMD for these studies, as shown in [Fig. 3](#f0015){ref-type="fig"} , suggesting a significant increase of D-dimer level in patients with severe disease than those with non-severe disease, on admission.Fig. 3Forest plot showing the weighted mean difference (WMD) of D-dimer values between patients with severe disease and those with non-severe disease.Fig. 3

3.4. Odds of severe COVID-19 in patients with abnormal D-dimer {#s0065}
--------------------------------------------------------------

For meta-analysis concerning the odds of severe COVID-19, 4 studies and our cohort study were included. The odds ratio of severe COVID-19 associated with D-dimer greater than 0.5 μg/ml was 5.78 (95% CI, 2.16--15.44, *p* \< 0.001, I^2^ = 87.2%, [Fig. 4](#f0020){ref-type="fig"} ), indicating that the severe COVID-19 was associated with increased level of D-dimer on admission.Fig. 4Forest plot showing the odds ratios (OR) with 95% confidence interval (95% CI) for severe COVID-19 in patients with D-dimer greater than 0.5 μg/ml compared to patients with normal D-dimer values.Fig. 4

3.5. Publication bias {#s0070}
---------------------

The funnel plots and the Egger\'s test (*p* = 0.01) for the studies reporting the absolute value of D-dimer showed that a publication bias existed in these studies ([Supplementary Fig. 1](#ec0005){ref-type="supplementary-material"}A). And no significant publication bias was detected among studies evaluating the odds of severe COVID-19 in patients with abnormal D-dimer, with Egger\'s test showing *p* = 0.794 ([Supplementary Fig. 1](#ec0005){ref-type="supplementary-material"}B).

4. Discussion {#s0075}
=============

Abnormal coagulation function, including elevated D-dimer, has been demonstrated to be involved in the disease progression of COVID-19 \[[@bb0025],[@bb0105]\]. In this study, we analyzed the association between elevated D-dimer levels and the disease severity of COVID-19 based on the evidence from our cohort study and meta-analysis. In our retrospective cohort study, the level of D-dimer was markedly increased in patients with severe COVID-19, and the meta-analysis further confirmed that odds of severe COVID-19 was associated with D-dimer greater than 0.5 μg/ml.

D-dimer assays are commonly used in clinical practice to exclude a diagnosis of deep vein thrombosis or pulmonary embolism, and elevated D-dimer indicates increased risk of abnormal blood clotting. Elevated levels of D-dimer were also found to be related with higher mortality rate of community-acquired pneumonia \[[@bb0110]\]. Patients with severe community-acquired pneumonia had significantly higher D-dimer levels, and D-dimer within normal range indicated low risk for complications \[[@bb0115]\]. Augmented activity of urokinase could cause hyperfibrinolysis, by increasing cleavage of plasminogen into the active plasmin, and finally led to diffuse alveolar damage and acute lung injury, in a mouse model of SARS-CoV disease \[[@bb0120]\]. In our cohort study, the level of coagulation function parameters, including prothrombin time, fibrinogen, fibrin(ogen) degradation products, and D-dimer, were found elevated in patients with severe COVID-19. Presumably, the severity of COVID-19 might also be associated with coagulation dysfunction.

Recent studies documenting the laboratory changes of patients with confirmed COVID-19 have noted that elevated D-dimer might be associated with the disease progression of COVID-19. The level of D-dimer in patients with COVID-19 admitted to the ICU was reported significantly increased \[[@bb0125]\]. Clinical attention to venous thromboembolism risk should particularly be paid to those patients with severe COVID-19, who were often bedridden and presented with abnormal coagulation function \[[@bb0125],[@bb0130]\]. Rapid deterioration was observed in cases with significantly increased D-dimer during the disease progression. In this regard, pulmonary embolism after deep vein thrombosis detachment should be considered and immediately on the alert, especially when patients presented clinical manifestations such as a rapid drop in blood pressure, sudden deterioration of oxygenation, and respiratory distress.

In addition to thrombosis and pulmonary embolism, D-dimer might be a manifestation of severe virus infection. A virus infection may develop into sepsis and induce coagulation dysfunction, which was common in serious disease progression. Moreover, the increase of D-dimer may be an indirect manifestation of inflammatory reaction, as inflammatory cytokines could cause the imbalance of coagulation and fibrinolysis in the alveoli, which may activate the fibrinolysis system, and then increase the level of D-dimer \[[@bb0135],[@bb0140]\]. And D-dimer greater than 1 μg/ml was found a risk factor of poor prognosis for patients with COVID-19 \[[@bb0030]\]. Abnormal levels of D-dimer were also associated with 28-day mortality in patients with COVID-19, and low molecular weight heparin treatment might be beneficial to COVID-19 patients with markedly elevated D-dimer (i.e. over 3 μg/ml) with reduced mortality rate \[[@bb0135]\].

There were several limitations in our study. Firstly, a significant degree of heterogeneity and a publication bias were detected in the meta-analysis, because most of included studies were retrospective and non-randomized controlled trial. Secondly, converting non-normally distributed statistics (median and range) to normally distributed statistics (mean and SD) may cause a bias, when evaluating the changes of D-dimer value between severe patients and non-severe patients. Thirdly, the methods of D-dimer assay were not clear in studies included in this meta-analysis. Finally, the odds of severe COVID-19 associated with abnormal level of D-dimer, was based on univariable analysis or obtained by calculation in some studies \[[@bb0015],[@bb0090], [@bb0095], [@bb0100]\]. Therefore, the bias may be inevitable.

Nevertheless, our study demonstrated that the D-dimer level in patients with severe COVID-19 was higher than that in mild cases. Thus, the evidence that patients with elevated D-dimer levels might have a higher risk of severe infection from our cohort study and the meta-analysis, provided a timely reminder to physicians that those COVID-19 patients with higher D-dimer should attract more attention in early time.

The following are the supplementary data related to this article.Supplementary Fig. 1Funnel plots of weighted mean difference (WMD) of D-dimer values (A) and univariate odds ratios (OR) for severe COVID-19 (B).Supplementary Fig. 1
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[^2]: Data are median (IQR), and n (%). *p* values were calculated from the comparison between patients with mild infection and patients with severe infection using χ^2^ test, Fisher\'s exact-test (for categorical variables), *t-*test or Mann-Whitney *U* test (for continuous variables).

[^3]: IQR = interquartile range. COVID-19 = coronavirus disease 2019.

[^4]: Statistically significant when *p* values were lower or equal as the Bonferroni corrected *p* value of 0.0063.

[^5]: *p* values were calculated from logistic regression analysis to estimate the odds ratio of presence of severe infection in patients with COVID-19.

[^6]: COVID-19 = coronavirus disease 2019; OR = odds ratio; CI = confidence interval.

[^7]: Prothrombin time, international normalized ratio and prothrombin activity are three different expressions of the same laboratory parameter, and only prothrombin time was included in the multivariable logistic regression model.

[^8]: Data of D-dimer value were shown in median (IQR). IQR = interquartile range.
